Company intelligence / Profile preview

VirRx

St. Louis, Missouri, United States

Ownership: Private
Development stage: Other

Overview

VirRx is a clinical-stage biotechnology company specializing in the development of oncolytic adenoviruses for cancer therapy. Founded on research from Saint Louis University, the company's technology focuses on enhancing the lytic potential of adenoviruses by overexpressing the Adenovirus Death Protein (ADP). This modification allows the virus to more efficiently kill cancer cells and spread within the tumor microenvironment. The lead candidate, VRX-007, has been evaluated in Phase 1 clinical trials for patients with various solid tumors. VirRx aims to leverage its viral engineering platform to create targeted, potent therapies for difficult-to-treat malignancies.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on VirRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VirRx.

Explore the full profile